An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2071-2081

  Leigh, J Paul ^a   White, Richard H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Cost effectiveness; Economics; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG COST; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMOPTYSIS; HOME CARE; HUMAN; INTRAOCULAR HEMATOMA; MAJOR CLINICAL STUDY; MALE; MUSCLE HEMATOMA; RECTUM HEMORRHAGE; SOCIOECONOMICS; STROKE; TONGUE HEMATOMA; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE; VAGINA BLEEDING; COHORT ANALYSIS; ECONOMICS; INTERNATIONAL NORMALIZED RATIO; ORAL DRUG ADMINISTRATION; PROBABILITY; STATISTICAL MODEL;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MARKOV CHAINS; MODELS, ECONOMIC;

EID: 36049037618     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210822     Document Type: Article

References (26)

1. European Heart Rhythm Association and the Heart Rhythm Society, Fusten V, Ryden LE, Cannon DS, et al. ACC/AHA/ ESC 2006 Guidelines for the management of patients with atrial fibrillation - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006;114:700-52
2. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6
3. Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost 2006;4:1180-5
4. Bushnell CD, Matchar DB. Pharmacoeconomics of atrial fibrillation and stroke prevention. Am J Managed Care 2004;10:S66-71
5. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006;96:274-84
6. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19
7. O'Brien CL, Gage BF. Costs and effectiveness of ximiligatran for stroke prophylaxis in chronic atrial fibrillation. J Am Med Assoc 2005;293:699-706
8. Hillinen T, Martikainen JA, Soini EJO, et al. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006;22:683-92
9. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal anticoagulation. Am J Managed Care 2004;10:S451-8
10. Go AS, Hylek EM, Chang Y, et al. Effect of intensity of oral anti-coagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
11. Hylek EM, Go AS, Chang Y, et al. Anticoagulation therapy for stroke precaution in atrial fibrillation: how well do randomized trails translate into clinical practice? J Am Med Assoc 2003;290:2685-92
12. Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 2006;166: 853-9
13. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation study. Ann Intern Med 1999;131:927-34
14. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. J Am Med Assoc 1995;274: 1839-45
15. Hart AC, Schmidt K. 2004 DRG Expert 20th Edition. Ingenix, St. Anthony Publishing, Salt Lake City, UT 2004
16. Wasserman Y. Physicians' Fee Reference 2004. 21st Edition, Yale Wasserman Medical Publishers, Milwaukee, Wisconsin, 2004
17. Bodenheimer TS, Grumback K. Understanding Health Policy: A Clinical Approach, 3rd edn. New York, NY: Lange Medical Books/McGraw-Hill, 2002
18. 2003 Drug Topics Red Book 10th edn. Montvale, NJ: Thompson PDR, 2003
19. Samsa GP, Matchar DB, Phillips DL, et al. Which approach to anticoagulation management is best?: Illustration of an interactive mathematical model to support informed decision making. J Thromb Thrombolysis 2002;14:103-11
20. Lafata JE, Martin SA, Kaatz S, et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis. J Thromb Thrombolysis 2000;Suppl 1:S13-19
21. Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31-7
22. Seto TB, Taira DA, Tsevat J, et al. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997;29:122-30
23. Gianetti J, Gensini G, De Caterina R. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy - equivalence of costs as a possible case for oral anticoagulants. Thromosis Haemostasis 1998;80:887-93
24. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998;29:1827-32
25. Marchetti M, Pistorio A, Barone M, et al. Low molecular weight heparin versus warfarin for secondary prophylaxis of venous-thromboembolism: a cost-effectiveness analysis. Am J Med 2001,111:130-9
26. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996;276:1172-7